Robust evidence from multiple landmark trials demonstrates their consistent ability to reduce major adverse cardiovascular events by 14%, with notable benefits extending beyond glycemic control
($5) Metallic Liquid Lipstick packs a lot of pigment and is on trend as it gets right now
The large cardiovascular outcomes trials of GLP-1 receptor agonists (LEADER, SUSTAIN-6 and REWIND) have confirmed that this class of medication can lower major adverse cardiovascular events by 12-14% in high-risk individuals, and the link between percent weight loss and cardiovascular risk reduction has led to the expectation that higher percent weight loss will yield greater incremental cardiovascular benefits if this class of drug can be used in combination with amylin receptor agonists
The onset varies widely, ranging from 2 weeks to 14 months after the initial ICI infusion
One study found that spirulina (blue-green algae) supports the growth of beneficial intestinal microbiota like Prevotella, Porphyromonadaceae, Barnesiella and Paraprevotella (14)
Studies show that magnesium reduces muscle soreness and damage, improves performance and recovery, and induces a protective effect on muscle damage
